ResearcherZhejiang Chinese Medical UniversityNo recent work listed

Liping Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3102-0640; OpenAlex author ID A5100430186. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper

Papers 1

Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. Co-author DOI 10.1016/j.phymed.2021.153537 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Di Feng · 1 shared paper, 2021 · strength 0.12
- Paper Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. DOI 10.1016/j.phymed.2021.153537 ↗
Yafang Qian · 1 shared paper, 2021 · strength 0.12
- Paper Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. DOI 10.1016/j.phymed.2021.153537 ↗
Mancang Gu · 1 shared paper, 2021 · strength 0.12
- Paper Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. DOI 10.1016/j.phymed.2021.153537 ↗
Yifan Qian · 1 shared paper, 2021 · strength 0.12
- Paper Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling. DOI 10.1016/j.phymed.2021.153537 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.